Compass Therapeutics (CMPX) 10-Q 12 Nov 24 2024 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Nov. 08, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-39696
Entity Registrant Name	COMPASS THERAPEUTICS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4876496
Entity Address, Address Line One	80 Guest St., Suite 601
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02135
City Area Code	617
Local Phone Number	500-8099
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	CMPX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		137,589,171
Entity Central Index Key	0001738021
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 36,801	$ 24,228
Marketable securities	98,601	128,233
Prepaid expenses and other current assets	5,738	1,420
Total current assets	141,140	153,881
Property and equipment, net	493	898
Operating lease, right-of-use ("ROU") asset	6,950	1,776
Other assets	568	320
Total assets	149,151	156,875
Current liabilities:
Accounts payable	960	4,090
Accrued expenses	2,916	2,514
Operating lease obligations, current portion	557	1,197
Total current liabilities	4,433	7,801
Operating lease obligations, long-term portion	6,320	536
Total liabilities	10,753	8,337
Commitments and Contingencies
Stockholders' equity:
Common stock, $0.0001 par value: 300,000 shares authorized; 137,589 and 127,668 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	14	13
Additional paid-in-capital	487,550	463,796
Accumulated other comprehensive income	486	37
Accumulated deficit	(349,652)	(315,308)
Total stockholders' equity	138,398	148,538
Total liabilities and stockholders' equity	$ 149,151	$ 156,875

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares shares in Thousands	Sep. 30, 2024	Dec. 31, 2023
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized (in shares)	300,000	300,000
Common Stock, Shares, Issued (in shares)	137,589	127,668
Common Stock, Shares, Outstanding (in shares)	137,589	127,668

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Licensing revenue	$ 0	$ 0	$ 850	$ 0
Research and development	8,612	8,831	29,304	25,694
General and administrative	3,627	3,095	11,597	9,276
Total operating expenses	12,239	11,926	40,901	34,970
Loss from operations	(12,239)	(11,926)	(40,051)	(34,970)
Other income	1,758	1,962	5,709	5,891
Net loss	(10,481)	(9,964)	(34,342)	(29,079)
Unrealized gain (loss) on marketable securities	577	77	449	(128)
Comprehensive loss	$ (9,904)	$ (9,887)	$ (33,893)	$ (29,207)
Net loss per share - basic and diluted (in dollars per share)	$ (0.08)	$ (0.08)	$ (0.25)	$ (0.23)
Basic and diluted weighted average shares outstanding (in shares)	137,589	127,424	137,263	126,837
Net loss	$ (10,481)	$ (9,964)	$ (34,342)	$ (29,079)
Unrealized gain (loss) on marketable securities	577	77	449	(128)
Comprehensive loss	$ (9,904)	$ (9,887)	$ (33,893)	$ (29,207)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022	126,302
Balance at Dec. 31, 2022	$ 13	$ 454,741	$ (302)	$ (272,814)	$ 181,638
Stock-based compensation	0	1,267	0	0	1,267
Unrealized gain (loss) on marketable securities	0	0	156	0	156
Net loss	$ 0	0	0	(7,837)	(7,837)
Balance (in shares) at Mar. 31, 2023	126,375
Balance at Mar. 31, 2023	$ 13	456,049	(146)	(280,651)	175,265
Vesting of share-based awards (in shares)	61
Vesting of share-based awards	$ 0	0	0	0	0
Common stock issued upon exercise of options (in shares)	12
Common stock issued upon exercise of options	$ 0	41	0	0	41
Stock-based compensation	$ 0	1,267	0	0	1,267
Balance (in shares) at Dec. 31, 2022	126,302
Balance at Dec. 31, 2022	$ 13	454,741	(302)	(272,814)	181,638
Unrealized gain (loss) on marketable securities					(128)
Net loss					(29,079)
Balance (in shares) at Sep. 30, 2023	127,445
Balance at Sep. 30, 2023	$ 13	462,355	(430)	(301,893)	160,045
Balance (in shares) at Mar. 31, 2023	126,375
Balance at Mar. 31, 2023	$ 13	456,049	(146)	(280,651)	175,265
Common shares issued, net of issuance costs (in shares)	952
Common shares issued, net of issuance costs	$ 0	3,032	0	0	3,032
Stock-based compensation	0	1,628	0	0	1,628
Unrealized gain (loss) on marketable securities	0	0	(361)	0	(361)
Net loss	$ 0	0	0	(11,278)	(11,278)
Balance (in shares) at Jun. 30, 2023	127,388
Balance at Jun. 30, 2023	$ 13	460,709	(507)	(291,929)	168,286
Vesting of share-based awards (in shares)	61
Vesting of share-based awards	$ 0	0	0	0	0
Stock-based compensation	0	1,628	0	0	1,628
Stock-based compensation	0	1,625	0	0	1,625
Unrealized gain (loss) on marketable securities	0	0	77	0	77
Net loss	$ 0	0	0	(9,964)	(9,964)
Balance (in shares) at Sep. 30, 2023	127,445
Balance at Sep. 30, 2023	$ 13	462,355	(430)	(301,893)	160,045
Vesting of share-based awards (in shares)	41
Vesting of share-based awards	$ 0	0	0	0	0
Common stock issued upon exercise of options (in shares)	16
Common stock issued upon exercise of options	$ 0	21	0	0	21
Stock-based compensation	$ 0	1,625	0	0	1,625
Balance (in shares) at Dec. 31, 2023	127,668
Balance at Dec. 31, 2023	$ 13	463,796	37	(315,308)	148,538
Common shares issued, net of issuance costs (in shares)	9,790
Common shares issued, net of issuance costs	$ 1	17,568	0	0	17,569
Share-based awards, net of tax remittance (in shares)	131
Share-based awards, net of tax remittance		(136)	0	0	(136)
Stock-based compensation	$ 0	2,003	0	0	2,003
Unrealized gain (loss) on marketable securities	0	0	(127)	0	(127)
Net loss	$ 0	0	0	(10,787)	(10,787)
Balance (in shares) at Mar. 31, 2024	137,589
Balance at Mar. 31, 2024	$ 14	483,231	(90)	(326,095)	157,060
Stock-based compensation	$ 0	2,003	0	0	2,003
Balance (in shares) at Dec. 31, 2023	127,668
Balance at Dec. 31, 2023	$ 13	463,796	37	(315,308)	148,538
Unrealized gain (loss) on marketable securities					449
Net loss					(34,342)
Balance (in shares) at Sep. 30, 2024	137,589
Balance at Sep. 30, 2024	$ 14	487,550	486	(349,652)	$ 138,398
Common stock issued upon exercise of options (in shares)					0
Balance (in shares) at Mar. 31, 2024	137,589
Balance at Mar. 31, 2024	$ 14	483,231	(90)	(326,095)	$ 157,060
Stock-based compensation	0	2,121	0	0	2,121
Unrealized gain (loss) on marketable securities	0	0	(1)	0	(1)
Net loss	$ 0	0	0	(13,076)	(13,076)
Balance (in shares) at Jun. 30, 2024	137,589
Balance at Jun. 30, 2024	$ 14	485,352	(91)	(339,171)	146,104
Stock-based compensation	0	2,121	0	0	2,121
Stock-based compensation	0	2,198	0	0	2,198
Unrealized gain (loss) on marketable securities	0	0	577	0	577
Net loss	$ 0	0	0	(10,481)	(10,481)
Balance (in shares) at Sep. 30, 2024	137,589
Balance at Sep. 30, 2024	$ 14	487,550	486	(349,652)	138,398
Stock-based compensation	$ 0	$ 2,198	$ 0	$ 0	$ 2,198

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Jun. 30, 2023
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 0.5	$ 0.1

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (34,342)	$ (29,079)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation and amortization	449	538
Share-based compensation	6,322	4,520
Amortization of premium and discount on marketable securities	(1,381)	(2,414)
ROU asset amortization	945	884
Increase (Decrease) in Operating Capital [Abstract]
Prepaid expenses and other current assets	4,318	(5,301)
Accounts payable	(3,130)	(1,076)
Accrued expenses	402	(6,046)
Operating lease liability	(640)	(892)
Net cash used in operating activities	(35,693)	(28,264)
Cash flows from investing activities:
Purchases of marketable securities	(78,297)	(110,339)
Proceeds from sale or maturities of marketable securities	109,743	131,011
Purchases of property and equipment	(44)	(21)
Net cash provided by investing activities	31,402	20,651
Net Cash Provided by (Used in) Financing Activities [Abstract]
Proceeds from issuance of common stock	(18,113)	(3,126)
Issuance costs from issuance of common stock	(545)	(95)
Taxes paid related to net shares settlement of RSUs	(136)	0
Proceeds from exercise of stock options	0	62
Net cash provided by financing activities	17,432	3,093
Net change in cash, cash equivalents and restricted cash	13,141	(4,520)
Cash, cash equivalents and restricted cash at beginning of period	24,228	34,946
Cash, cash equivalents and restricted cash at end of period	37,369	30,426
Supplemental Cash Flow Information [Abstract]
Unrealized loss (gain) on marketable securities	$ (449)	$ 128

Note 1 - Nature of Business and

Note 1 - Nature of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Nature of Business and Basis of Presentation Compass Therapeutics, Inc. (“Compass” or the “Company”) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis and the immune system. Our pipeline includes novel product candidates that leverage our understanding of the tumor microenvironment, including both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed to optimize critical components required for an effective anti-tumor response to cancer. These include modulation of the microvasculature via angiogenesis-targeted agents; induction of a potent immune response via activators on effector cells in the tumor microenvironment; and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. We plan to advance our product candidates through clinical development as both standalone therapies and in combination with our proprietary drug candidates as long as their continued development is supported by clinical and nonclinical data. References to Compass or the Company herein include Compass Therapeutics, Inc. and its wholly-owned subsidiaries. The Company is subject to risks and uncertainties common to companies in the biotechnology and pharmaceutical industries. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s consolidated financial position as of September 30, 2024 and its consolidated results of operations, comprehensive loss and changes in stockholders’ equity for the three and nine months ended September 30, 2024 and 2023 and cash flows for the nine months ended September 30, 2024 and 2023. Operating results for the nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The unaudited condensed consolidated financial statements include the accounts of Compass Therapeutics, Inc. and its subsidiaries, and have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 Liquidity Since our inception, we have devoted substantially all of our efforts to organizing and staffing our Company, business planning, raising capital, research and development activities, building our intellectual property portfolio and providing general and administrative support for these operations. We have funded our operations with proceeds from the sale of our equity securities and borrowing from debt arrangements. Through September 30, 2024, we have received $430 million in gross proceeds from the sale of equity securities. As of September 30, 2024, we had cash and marketable securities of $135 million. Based on our research and development plans, we expect that such cash resources will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2027.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies There have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report.

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The following tables represent the Company’s financial assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): Fair Value Measurements as of September 30, 2024 (000's): Quoted Prices in Significant Other Significant Fair Value Assets Corporate bonds $ — $ 55,766 $ — $ 55,766 Commercial paper 14,302 — — 14,302 Certificates of deposit — 15,728 — 15,728 U.S. government treasuries 4,448 — — 4,448 Asset-backed securities — 8,357 — 8,357 Total assets $ 18,750 $ 79,851 $ — $ 98,601 Fair Value Measurements as of December 31, 2023 (000's): Quoted Prices in Significant Other Significant Fair Value Assets Corporate bonds $ — $ 54,281 $ — $ 54,281 Commercial paper 28,534 — — 28,534 Certificates of deposit — 18,866 — 18,866 U.S. government treasuries 16,080 — — 16,080 Asset-backed securities — 10,472 — 10,472 Money market funds (cash equivalents) 575 — — 575 Total assets $ 45,189 $ 83,619 $ — $ 128,808

Note 4 - Marketable Securities

Note 4 - Marketable Securities	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	4. Marketable Securities The objectives of the Company’s investment policy are to ensure the safety and preservation of invested funds, as well as to maintain liquidity sufficient to meet cash flow requirements. The Company invests its excess cash in securities issued by financial institutions, commercial companies, and government agencies that management believes to be of high credit quality in order to limit the amount of its credit exposure. The Company has not realized any net losses from its investments. Unrealized gains and losses on investments that are available for sale are recognized in accumulated other comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are included in other income in the condensed consolidated statements of operations and comprehensive loss and are determined using the specific identification method with transactions recorded on a trade date basis. The Company classifies marketable securities that are available for use in current operations as current assets on the condensed consolidated balance sheet. The following tables summarize marketable securities held (in thousands): Fair Value Measurements as of September 30, 2024 Using: Amortized Cost Unrealized gains Unrealized Losses Fair Value Assets Corporate bonds $ 55,375 $ 392 $ (1 ) $ 55,766 Commercial paper 14,285 17 — 14,302 Certificates of deposit 15,711 17 — 15,728 U.S. government treasuries 4,442 9 (3 ) 4,448 Asset-backed securities 8,302 56 (1 ) 8,357 Total assets $ 98,115 $ 491 $ (5 ) $ 98,601 Fair Value Measurements as of December 31, 2023 Using: Amortized Cost Unrealized gains Unrealized Losses Fair Value Assets Corporate bonds $ 54,256 $ 74 $ (49 ) $ 54,281 Commercial paper 28,507 30 (3 ) 28,534 Certificates of deposit 18,850 17 (1 ) 18,866 U.S. government treasuries 16,127 3 (50 ) 16,080 Asset-backed securities 10,456 23 (7 ) 10,472 Total assets $ 128,196 $ 147 $ (110 ) $ 128,233 As of September 30, 2024 December 31, 2023 Maturing in one year or less $ 62,588 $ 93,117 Maturing after one year through two years 36,013 35,116 Total $ 98,601 $ 128,233

Note 5 - Property and Equipment

Note 5 - Property and Equipment	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment Property and equipment consist of the following (in thousands): September 30, December 31, Equipment $ 5,211 $ 5,167 Leasehold improvements 1,612 1,612 Software 364 364 Furniture and fixtures 22 22 Total property and equipment–at cost 7,209 7,165 Less: Accumulated depreciation (6,716 ) (6,267 ) Property and equipment, net $ 493 $ 898 Depreciation and amortization expense for the nine months ended September 30, 2024 and 2023 was $0.5 million.

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued Expenses Accrued expenses consist of the following (in thousands): September 30, December 31, 2024 2023 Project expenses $ 64 $ 336 Compensation and benefits 2,685 1,938 Other 167 240 Total accrued expenses $ 2,916 $ 2,514

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies Leases The Company has evaluated its leases under ASC 842, Leases When available, the Company will use the rate implicit in the lease to discount lease payments to present value; however, the Company’s current lease does not provide an implicit rate. Therefore, the Company used its incremental borrowing rate of 6.25% to discount the lease payments based on the date of the lease commencement. The Company has one four The terms of the Facility lease were modified effective September 27, 2024 through the execution of a new lease. The modified terms extended the non-cancelable lease term through May 2031. The modified terms also included the right to use an additional 10,724 square feet that is expected to commence and be available for the Company’s use in May 2025. The classification and incremental borrowing rate for the lease did not change as a result of this lease modification. Right-of-use assets obtained in exchange for new operating lease liabilities due to the lease modification were $6.1 million for a total right-of-use assets as of September 30, 2024 of $7.0 million. The remaining lease term of the Facility lease is 6.7 years as of September 30, 2024. The Company has $568 thousand of restricted cash associated with an irrevocable letter of credit required by the landlord to enter into this lease. Lease costs related to the Facility were $0.3 million for the three months ending September 30, 2024 and 2023 and $1.0 million for the nine months ending September 30, 2024 and 2023. Cash payments related to the Facility were $0.3 million for the three months ending September 30, 2024 and 2023 and $1.0 million for the nine months ending September 30, 2024 and 2023. The table below presents the undiscounted cash flows for the lease term. The undiscounted cash flows are reconciled to the operating lease liabilities recorded on the condensed consolidated balance sheet (in thousands): Remainder of 2024 $ 348 2025 733 2026 1,018 2027 1,412 2028 1,441 Thereafter 3,614 Total minimum lease payments 8,566 Less: amount of lease payments representing interest (1,689 ) Present value of future minimum lease payments 6,877 Less: operating lease obligations, current portion (557 ) Operating lease obligations, long-term portion $ 6,320 Defined Contribution Plan The Company has a 401(k) defined contribution plan (the “401(k) Plan”) for substantially all its employees. Eligible employees may make pre-tax or post-tax (Roth) contributions to the 401(k) Plan up to statutory limits. Since January 1, 2020, the Company has been matching employee contributions to the plan up to 4% of salary. On July 1, 2023, the Company increased the employee matching contribution from 4% to 6%. The Company made matching contributions of $0.1 million and $0.1 million for the three months ended September 30, 2024 and 2023, respectively. The Company made matching contributions of $0.3 million and $0.2 million for the nine months ended September 30, 2024 and 2023, respectively.

Note 8 - Stock-based Compensati

Note 8 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	8. Stock-Based Compensation Stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 was classified in the condensed consolidated statement of operations as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (000’s) (000’s) Research and development $ 244 $ 159 $ 1,626 $ 387 General and administrative 1,954 1,466 4,696 4,133 Total $ 2,198 $ 1,625 $ 6,322 $ 4,520 As of September 30, 2024, remaining unrecognized stock-based compensation cost from all plans to be recognized in future periods totaled $19.2 million. 2020 Plan In June 2020, the Company’s board of directors adopted the 2020 Stock Option and Incentive Plan (the “2020 Plan”) and reserved 2.9 million shares of common stock for issuance under this plan. The 2020 Plan includes automatic annual increases. The increase on January 1, 2024 was 5.1 million shares. As of September 30, 2024, 2.2 million shares remain available for grant. The 2020 Plan authorizes the board of directors or a committee of the board to grant incentive stock options, nonqualified stock options, restricted stock awards and restricted stock units ("RSUs") to eligible officers, employees, consultants and directors of the Company. Options generally vest over a period of four ten Stock Options: The following table summarizes the stock option activity for the 2020 Plan: Weighted Weighted Number of Average Average Aggregate Unvested Exercise Remaining Intrinsic Options Price Contractual Value (000's) Per Share Term (in years) ($000's) Outstanding at December 31, 2023 7,876 $ 3.81 8.05 $ 11 Granted 5,753 $ 1.57 7.13 — Exercised — $ — — — Forfeited/canceled (4 ) $ 3.26 — — Outstanding at September 30, 2024 13,625 $ 2.87 6.36 $ 1,795 Vested at September 30, 2024 5,780 $ 3.82 5.38 $ 99 For the nine months ended September 30, 2024, the weighted average grant date fair value for options granted was $1.13. The outstanding options had an intrinsic value as of September 30, 2024 of $1.8 million. As of September 30, 2024, the total unrecognized compensation cost related to outstanding options was $12.0 million, to be recognized over a weighted average period of 1.5 years. For the nine months ended September 30, 2023, the weighted average grant date fair value for options granted was $2.82. The intrinsic value for options vested as of September 30, 2023, was $34 thousand. As of September 30, 2023, the total unrecognized compensation cost related to outstanding options was $10.4 million, to be recognized over a weighted average period of 2.8 years. The weighted average assumptions used in the Black-Scholes pricing model to determine the fair value of stock options granted during the nine months ended September 30, 2024 and 2023 were as follows: Nine Months Ended September 30, 2024 2023 Expected term (in years) 6.0 6.0 Risk-free rate 3.9 % 3.8 % Expected volatility 81 % 88 % Expected dividend yield — As of January 2024, the Company used the historical price of only its own stock to determine the expected volatility. Prior to this, a group of industry peers, including the Company’s stock price, was used. RSUs: The following table summarizes the RSU activity for the 2020 Plan: Shares Weighted Weighted Unvested, December 31, 2023 1,500 $ 3.89 $ 5,835 Granted 2,391 1.93 4,615 Vested (225 ) 3.93 (884 ) Forfeited or canceled — — — Unvested, September 30, 2024 3,666 $ 2.61 $ 9,565 The weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants. The weighted average fair value is the weighted average share price times the number of shares.

Note 9 - Related Parties and Re

Note 9 - Related Parties and Related-Party Transactions	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	9. Related Parties and Related-Party Transactions There were no material related party transactions during the nine months ended September 30, 2024 and 2023.

Note 10 - Other Income

Note 10 - Other Income	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Other Nonoperating Income and Expense [Text Block]	10. Other Income Other income consists exclusively of interest income of $1.8 million and $2.0 million for the three months ended September 30, 2024 and 2023, respectively. Interest income was $5.7 million and $5.9 million for the nine months ended September 30, 2024 and 2023, respectively

Note 11 - License, Research and

Note 11 - License, Research and Collaboration Agreements	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	11. License, Research and Collaboration Agreements Collaboration Agreements ABL Bio Corporation ("ABL Bio") Agreement In November 2018, the Company and ABL Bio, a South Korean biotechnology company, entered into an exclusive global (excluding South Korea) license agreement which granted the Company a license to CTX-009 (ABL001), ABL Bio’s bispecific antibody targeting DLL4 and VEGF-A. Under the terms of the agreement, the two companies would jointly develop CTX-009, with ABL Bio responsible for development of CTX-009 throughout the end of Phase 1 clinical trials and the Company responsible for the development of CTX-009 from Phase 2 and onward. ABL Bio received a $5 million upfront payment and $6 million development milestone payment. In addition, ABL Bio is eligible to receive up to $96 million of development and regulatory milestone payments, and up to $303 million of commercial milestone payments and tiered single-digit royalties on net sales of CTX-009 in oncology. ABL Bio is also eligible to receive up to $75 million in development and regulatory milestones and up to $110 million in commercial milestone payments and tiered, single-digit royalties on net sales of CTX-009 in ophthalmology. In May 2021, the Company and ABL Bio terminated license agreements to several preclinical assets. As a result of the return of these assets to ABL Bio and termination of the license agreements, the Company is eligible to receive royalty payments if ABL Bio develops or licenses two bispecific antibodies that were previously licensed to the Company. Adimab Agreement The Company entered into a collaboration agreement with Adimab, LLC on October 16, 2014. The agreement includes provisions for payment of royalties at rates ranging in the single digits as a percentage of future net sales within a specified term from the first commercial sale for certain antibodies, including our product candidate, CTX-471. There were no milestone payments made during the first nine months of 2024. As of September 30, 2024, future potential milestone payments in connection with this agreement amounted to $2.0 million. Elpiscience Agreement The Company entered into a license agreement with Elpiscience Biopharmaceuticals Co., Limited (“Elpiscience”) on January 16, 2021. Under the agreement, the Company granted certain rights, including to develop, manufacture and commercialize CTX-009, to Elpiscience for the territory of Mainland China, Hong Kong, Taiwan and Macau in exchange for royalties and milestones. In April 2024, Elpiscience completed its phase 1 clinical trial which required a $1 million milestone payment due to the Company. Per the ABL Bio Agreement noted in this footnote, sub-licensing revenue is subject to a 15% royalty. License revenue reflects the $1 million, net of the ABL Bio royalty. License revenue is shown net of this royalty.

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Equity [Text Block]	12. Stockholders Equity In the quarter ended March 31, 2024, the Company sold through its at-the-market (“ATM”) agreement with Jefferies LLC, 9,790,577 shares of common stock at an average price of $1.85 for total proceeds of $18.1 million and net proceeds of $17.6 million. The Company did not

Insider Trading Arrangements

Insider Trading Arrangements	9 Months Ended
	Sep. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	Item 5. Other Information. During the three-month period ended September 30, 2024, none
Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Measurements as of September 30, 2024 (000's): Quoted Prices in Significant Other Significant Fair Value Assets Corporate bonds $ — $ 55,766 $ — $ 55,766 Commercial paper 14,302 — — 14,302 Certificates of deposit — 15,728 — 15,728 U.S. government treasuries 4,448 — — 4,448 Asset-backed securities — 8,357 — 8,357 Total assets $ 18,750 $ 79,851 $ — $ 98,601 Fair Value Measurements as of December 31, 2023 (000's): Quoted Prices in Significant Other Significant Fair Value Assets Corporate bonds $ — $ 54,281 $ — $ 54,281 Commercial paper 28,534 — — 28,534 Certificates of deposit — 18,866 — 18,866 U.S. government treasuries 16,080 — — 16,080 Asset-backed securities — 10,472 — 10,472 Money market funds (cash equivalents) 575 — — 575 Total assets $ 45,189 $ 83,619 $ — $ 128,808

Note 4 - Marketable Securities

Note 4 - Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Marketable Securities [Table Text Block]	Fair Value Measurements as of September 30, 2024 Using: Amortized Cost Unrealized gains Unrealized Losses Fair Value Assets Corporate bonds $ 55,375 $ 392 $ (1 ) $ 55,766 Commercial paper 14,285 17 — 14,302 Certificates of deposit 15,711 17 — 15,728 U.S. government treasuries 4,442 9 (3 ) 4,448 Asset-backed securities 8,302 56 (1 ) 8,357 Total assets $ 98,115 $ 491 $ (5 ) $ 98,601 Fair Value Measurements as of December 31, 2023 Using: Amortized Cost Unrealized gains Unrealized Losses Fair Value Assets Corporate bonds $ 54,256 $ 74 $ (49 ) $ 54,281 Commercial paper 28,507 30 (3 ) 28,534 Certificates of deposit 18,850 17 (1 ) 18,866 U.S. government treasuries 16,127 3 (50 ) 16,080 Asset-backed securities 10,456 23 (7 ) 10,472 Total assets $ 128,196 $ 147 $ (110 ) $ 128,233
Investments Classified by Contractual Maturity Date [Table Text Block]	As of September 30, 2024 December 31, 2023 Maturing in one year or less $ 62,588 $ 93,117 Maturing after one year through two years 36,013 35,116 Total $ 98,601 $ 128,233

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, December 31, Equipment $ 5,211 $ 5,167 Leasehold improvements 1,612 1,612 Software 364 364 Furniture and fixtures 22 22 Total property and equipment–at cost 7,209 7,165 Less: Accumulated depreciation (6,716 ) (6,267 ) Property and equipment, net $ 493 $ 898

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, 2024 2023 Project expenses $ 64 $ 336 Compensation and benefits 2,685 1,938 Other 167 240 Total accrued expenses $ 2,916 $ 2,514

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Remainder of 2024 $ 348 2025 733 2026 1,018 2027 1,412 2028 1,441 Thereafter 3,614 Total minimum lease payments 8,566 Less: amount of lease payments representing interest (1,689 ) Present value of future minimum lease payments 6,877 Less: operating lease obligations, current portion (557 ) Operating lease obligations, long-term portion $ 6,320

Note 8 - Stock-based Compensa_2

Note 8 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (000’s) (000’s) Research and development $ 244 $ 159 $ 1,626 $ 387 General and administrative 1,954 1,466 4,696 4,133 Total $ 2,198 $ 1,625 $ 6,322 $ 4,520
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Weighted Number of Average Average Aggregate Unvested Exercise Remaining Intrinsic Options Price Contractual Value (000's) Per Share Term (in years) ($000's) Outstanding at December 31, 2023 7,876 $ 3.81 8.05 $ 11 Granted 5,753 $ 1.57 7.13 — Exercised — $ — — — Forfeited/canceled (4 ) $ 3.26 — — Outstanding at September 30, 2024 13,625 $ 2.87 6.36 $ 1,795 Vested at September 30, 2024 5,780 $ 3.82 5.38 $ 99
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended September 30, 2024 2023 Expected term (in years) 6.0 6.0 Risk-free rate 3.9 % 3.8 % Expected volatility 81 % 88 % Expected dividend yield —
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Shares Weighted Weighted Unvested, December 31, 2023 1,500 $ 3.89 $ 5,835 Granted 2,391 1.93 4,615 Vested (225 ) 3.93 (884 ) Forfeited or canceled — — — Unvested, September 30, 2024 3,666 $ 2.61 $ 9,565

Note 1 - Nature of Business a_2

Note 1 - Nature of Business and Basis of Presentation (Details Textual) $ in Millions	78 Months Ended
	Sep. 30, 2024 USD ($)
Proceeds from Issuance or Sale of Equity	$ 430
Cash and Marketable Securities	$ 135

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Marketable Securities	$ 98,601	$ 128,233
Corporate Debt Securities [Member]
Marketable Securities	55,766	54,281
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Marketable Securities	14,302	28,534
Certificates of Deposit [Member]
Marketable Securities	15,728	18,866
US Treasury Securities [Member]
Marketable Securities	4,448	16,080
Asset-Backed Securities [Member]
Marketable Securities	8,357	10,472
Fair Value, Recurring [Member]
Total assets	98,601	128,808
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Marketable Securities	55,766	54,281
Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Marketable Securities	14,302	28,534
Fair Value, Recurring [Member] | Certificates of Deposit [Member]
Marketable Securities	15,728	18,866
Fair Value, Recurring [Member] | US Treasury Securities [Member]
Marketable Securities	4,448	16,080
Fair Value, Recurring [Member] | Asset-Backed Securities [Member]
Marketable Securities	8,357	10,472
Fair Value, Recurring [Member] | Money Market Funds [Member]
Money market funds (cash equivalents)		575
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Total assets	18,750	45,189
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]
Marketable Securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Marketable Securities	14,302	28,534
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member]
Marketable Securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Marketable Securities	4,448	16,080
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Asset-Backed Securities [Member]
Marketable Securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Money market funds (cash equivalents)		575
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Total assets	79,851	83,619
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]
Marketable Securities	55,766	54,281
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Marketable Securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]
Marketable Securities	15,728	18,866
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Marketable Securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Asset-Backed Securities [Member]
Marketable Securities	8,357	10,472
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Money market funds (cash equivalents)		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Total assets	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]
Marketable Securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Marketable Securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Certificates of Deposit [Member]
Marketable Securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Marketable Securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Asset-Backed Securities [Member]
Marketable Securities	$ 0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Money market funds (cash equivalents)		$ 0

Note 4 - Marketable Securitie_2

Note 4 - Marketable Securities - Marketable Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Amortized Cost	$ 98,115	$ 128,196
Unrealized gains	491	147
Unrealized Losses	(5)	(110)
Fair Value	98,601	128,233
Marketable Securities	98,601	128,233
Corporate Debt Securities [Member]
Amortized Cost	55,375	54,256
Unrealized gains	392	74
Unrealized Losses	(1)	(49)
Fair Value	55,766	54,281
Marketable Securities	55,766	54,281
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Amortized Cost	14,285	28,507
Unrealized gains	17	30
Unrealized Losses	0	(3)
Fair Value	14,302	28,534
Marketable Securities	14,302	28,534
Certificates of Deposit [Member]
Amortized Cost	15,711	18,850
Unrealized gains	17	17
Unrealized Losses	0	(1)
Fair Value	15,728	18,866
Marketable Securities	15,728	18,866
US Treasury Securities [Member]
Amortized Cost	4,442	16,127
Unrealized gains	9	3
Unrealized Losses	(3)	(50)
Fair Value	4,448	16,080
Marketable Securities	4,448	16,080
Asset-Backed Securities [Member]
Amortized Cost	8,302	10,456
Unrealized gains	56	23
Unrealized Losses	(1)	(7)
Fair Value	8,357	10,472
Marketable Securities	$ 8,357	$ 10,472

Note 4 - Marketable Securitie_3

Note 4 - Marketable Securities - Maturity (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Maturing in one year or less	$ 62,588	$ 93,117
Maturing after one year through two years	36,013	35,116
Total	$ 98,601	$ 128,233

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details Textual) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Depreciation	$ 0.5	$ 0.5

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Total property and equipment–at cost	$ 7,209	$ 7,165
Less: Accumulated depreciation	(6,716)	(6,267)
Property and equipment, net	493	898
Equipment [Member]
Total property and equipment–at cost	5,211	5,167
Leasehold Improvements [Member]
Total property and equipment–at cost	1,612	1,612
Software Development [Member]
Total property and equipment–at cost	364	364
Furniture and Fixtures [Member]
Total property and equipment–at cost	$ 22	$ 22

Note 6 - Accrued Expenses - Sch

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Project expenses	$ 64	$ 336
Compensation and benefits	2,685	1,938
Other	167	240
Total accrued expenses	$ 2,916	$ 2,514

Note 7 - Commitments and Cont_3

Note 7 - Commitments and Contingencies (Details Textual) $ in Thousands		2 Months Ended	3 Months Ended		9 Months Ended		57 Months Ended
	Jul. 01, 2023	Sep. 27, 2024 USD ($) ft²	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jan. 01, 2021	Dec. 31, 2020
Operating Lease, Right-of-Use Asset			$ 6,950		$ 6,950		$ 6,950	$ 1,776
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4%						4%
Defined Contribution Plan, Cost			$ 100	$ 100	$ 300	$ 200
Maximum [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	6%
Facility Lease [Member]
Lessee, Operating Lease, Discount Rate			6.25%		6.25%		6.25%
Number of Operating Leases										1
Lessee, Operating Lease, Term of Contract (Year)									4 years 5 months 1 day
Area of Real Estate Property | ft²		10,724
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability		$ 6,100
Operating Lease, Right-of-Use Asset			$ 7,000		$ 7,000		$ 7,000
Lessee, Operating Lease, Remaining Lease Term			6 years 8 months 12 days		6 years 8 months 12 days		6 years 8 months 12 days
Operating Lease, Cost			$ 300	300	$ 1,000	1,000
Operating Lease, Payments			$ 300	$ 300	$ 1,000	$ 1,000
Facility Lease [Member] | Financial Standby Letter of Credit [Member]
Restricted Cash		$ 568

Note 7 - Commitments and Cont_4

Note 7 - Commitments and Contingencies - Undiscounted Cash Flows Reconciled to Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Remainder of 2024	$ 348
2025	733
2026	1,018
2027	1,412
2028	1,441
Thereafter	3,614
Total minimum lease payments	8,566
Less: amount of lease payments representing interest	(1,689)
Present value of future minimum lease payments	6,877
Less: operating lease obligations, current portion	(557)	$ (1,197)
Operating lease obligations, long-term portion	$ 6,320	$ 536

Note 8 - Stock-based Compensa_3

Note 8 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions		9 Months Ended
	Jan. 01, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jun. 30, 2020
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		$ 19,200
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 1.13	$ 2.82
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value		$ 1,795		$ 11
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		12,000	$ 10,400
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value		$ 99	$ 34,000
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		1 year 6 months	2 years 9 months 18 days
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		$ 7,200
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		1 year 6 months
The 2020 Stock Option and Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized					2.9
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized	5.1
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant		2.2
The 2020 Stock Option and Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		4 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		10 years

Note 8 - Stock-based Compensa_4

Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Stock-based compensation expense	$ 2,198	$ 1,625	$ 6,322	$ 4,520
Research and Development Expense [Member]
Stock-based compensation expense	244	159	1,626	387
General and Administrative Expense [Member]
Stock-based compensation expense	$ 1,954	$ 1,466	$ 4,696	$ 4,133

Note 8 - Stock-based Compensa_5

Note 8 - Stock-based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023
Outstanding, options (in shares)	7,876
Outstanding, weighted average exercise price (in dollars per share)	$ 3.81
Outstanding, weighted average remaining contractual term (Year)	6 years 4 months 9 days	8 years 18 days
Outstanding, aggregate intrinsic value	$ 1,795	$ 11
Granted, options (in shares)	5,753
Granted, weighted average exercise price (in dollars per share)	$ 1.57
Granted, weighted average remaining contractual term (Year)	7 years 1 month 17 days
Exercised, options (in shares)	0
Exercised, weighted average exercise price (in dollars per share)	$ 0
Forfeited/canceled, options (in shares)	(4)
Forfeited/canceled, weighted average exercise price (in dollars per share)	$ 3.26
Outstanding, options (in shares)	13,625	7,876
Outstanding, weighted average exercise price (in dollars per share)	$ 2.87	$ 3.81
Vested, options (in shares)	5,780
Vested, weighted average exercise price (in dollars per share)	$ 3.82
Vested, weighted average remaining contractual term (Year)	5 years 4 months 17 days
Vested, aggregate intrinsic value	$ 99		$ 34,000

Note 8 - Stock-based Compensa_6

Note 8 - Stock-based Compensation - Weighted Average Assumptions (Details)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Expected term (in years) (Year)	6 years	6 years
Risk-free rate	3.90%	3.80%
Expected volatility	81%	88%

Note 8 - Stock-based Compensa_7

Note 8 - Stock-based Compensation - Summary of RSU Activity (Details) - Restricted Stock Units (RSUs) [Member] $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Unvested, balance (in shares) | shares	1,500
Unvested, weighted average price per share (in dollars per share) | $ / shares	$ 3.89
Unvested, weighted average fair value | $	$ 5,835
Granted (in shares) | shares	2,391
Granted, weighted average price per share (in dollars per share) | $ / shares	$ 1.93
Granted, weighted average fair value | $	$ 4,615
Vested (in shares) | shares	225
Vested, weighted average price per share (in dollars per share) | $ / shares	$ 3.93
Vested, weighted average fair value | $	$ 884
Forfeited or canceled (in shares) | shares	0
Forfeited or canceled, weighted average price per share (in dollars per share) | $ / shares	$ 0
Unvested, balance (in shares) | shares	3,666
Unvested, weighted average price per share (in dollars per share) | $ / shares	$ 2.61
Unvested, weighted average fair value | $	$ 9,565

Note 10 - Other Income (Details

Note 10 - Other Income (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Investment Income, Interest	$ 1.8	$ 2	$ 5.7	$ 5.9

Note 11 - License, Research a_2

Note 11 - License, Research and Collaboration Agreements (Details Textual) - USD ($) $ in Thousands	1 Months Ended		9 Months Ended
	Apr. 30, 2024	Nov. 30, 2018	Sep. 30, 2024
ABL Bio Agreement [Member]
Upfront Payment		$ 5,000
Development Milestone Payment		6,000
Maximum Development and Regulatory Milestone Payments		96,000
ABL Bio Agreement [Member] | Oncology [Member]
Maximum Commercial Milestone Payments and Royalties		303,000
ABL Bio Agreement [Member] | Ophthalmology [Member]
Maximum Development and Regulatory Milestone Payments		75,000
Maximum Commercial Milestone Payments and Royalties		$ 110,000
Adimab Agreement [Member]
Milestone Payments Paid			$ 0
Milestone Payment Obligation			$ 2,000
Elpiscience Agreement [Member]
Milestone Payments Paid	$ 1,000
Sublicensing Revenue Percentage	15%
Sublicensing Revenue Obligation	$ 1,000

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2023
Proceeds from Issuance of Common Stock			$ 18,113	$ 3,126
At The Market [Member]
Stock Issued During Period, Shares, New Issues	0	9,790,577
Shares Issued, Price Per Share		$ 1.85
Proceeds from Issuance of Common Stock		$ 18,100
Proceeds from Issuance of Common Stock, Net		$ 17,600